CO2023018656A2 - Sistemas de edición de genes que comprenden un arn guía dirigido a hidroxiácido oxidasa 1 (hao1) y usos de estos - Google Patents
Sistemas de edición de genes que comprenden un arn guía dirigido a hidroxiácido oxidasa 1 (hao1) y usos de estosInfo
- Publication number
- CO2023018656A2 CO2023018656A2 CONC2023/0018656A CO2023018656A CO2023018656A2 CO 2023018656 A2 CO2023018656 A2 CO 2023018656A2 CO 2023018656 A CO2023018656 A CO 2023018656A CO 2023018656 A2 CO2023018656 A2 CO 2023018656A2
- Authority
- CO
- Colombia
- Prior art keywords
- hao1
- gene editing
- guide rna
- hydroxy acid
- acid oxidase
- Prior art date
Links
- 238000010362 genome editing Methods 0.000 title abstract 5
- 102100038837 2-Hydroxyacid oxidase 1 Human genes 0.000 title abstract 2
- 108020005004 Guide RNA Proteins 0.000 title abstract 2
- 108010062584 glycollate oxidase Proteins 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 101150105486 HAO1 gene Proteins 0.000 abstract 2
- 208000004777 Primary Hyperoxaluria Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 101001031589 Homo sapiens 2-Hydroxyacid oxidase 1 Proteins 0.000 abstract 1
- 101150010487 are gene Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
- C12Y101/03015—(S)-2-Hydroxy-acid oxidase (1.1.3.15)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En la presente se proporcionan sistemas de edición de genes y/o composiciones que comprenden ARN guías que se dirigen a HAO1 para usar en edición genética del gen HAO1. También se proporcionan en la presente métodos para utilizar el sistema de edición de genes para introducir ediciones al gen HAO1 y/o para el tratamiento de hiperoxaluria primaria (PH), y procesos para caracterizar el sistema de edición de genes.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163197073P | 2021-06-04 | 2021-06-04 | |
US202163225046P | 2021-07-23 | 2021-07-23 | |
US202163292889P | 2021-12-22 | 2021-12-22 | |
US202263300727P | 2022-01-19 | 2022-01-19 | |
PCT/US2022/032144 WO2022256642A2 (en) | 2021-06-04 | 2022-06-03 | Gene editing systems comprising an rna guide targeting hydroxyacid oxidase 1 (hao1) and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2023018656A2 true CO2023018656A2 (es) | 2024-01-25 |
Family
ID=82694238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2023/0018656A CO2023018656A2 (es) | 2021-06-04 | 2023-12-29 | Sistemas de edición de genes que comprenden un arn guía dirigido a hidroxiácido oxidasa 1 (hao1) y usos de estos |
Country Status (10)
Country | Link |
---|---|
US (2) | US20230032141A1 (es) |
EP (1) | EP4347833A2 (es) |
JP (1) | JP2024520691A (es) |
KR (1) | KR20240034746A (es) |
AU (1) | AU2022283922A1 (es) |
CA (1) | CA3222159A1 (es) |
CO (1) | CO2023018656A2 (es) |
IL (1) | IL308803A (es) |
TW (1) | TW202317763A (es) |
WO (1) | WO2022256642A2 (es) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3087184B1 (en) * | 2013-12-27 | 2019-07-03 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna |
DE202019005567U1 (de) * | 2018-03-14 | 2021-02-16 | Arbor Biotechnologies, Inc. | Neue CRISPR-DNA-Targeting-Enzyme und -Systeme |
WO2020028327A1 (en) * | 2018-07-31 | 2020-02-06 | Intellia Therapeutics, Inc. | Compositions and methods for hydroxyacid oxidase 1 ( hao1) gene editing for treating primary hyperoxaluria type 1 (ph1) |
US20230332119A1 (en) * | 2020-03-31 | 2023-10-19 | Arbor Biotechnologies, Inc. | Compositions comprising a cas12i2 variant polypeptide and uses thereof |
US20230235305A1 (en) * | 2020-06-16 | 2023-07-27 | Arbor Biotechnologies, Inc. | Cells modified by a cas12i polypeptide |
CN113308451B (zh) * | 2020-12-07 | 2023-07-25 | 中国科学院动物研究所 | 工程化的Cas效应蛋白及其使用方法 |
-
2022
- 2022-06-03 WO PCT/US2022/032144 patent/WO2022256642A2/en active Application Filing
- 2022-06-03 IL IL308803A patent/IL308803A/en unknown
- 2022-06-03 CA CA3222159A patent/CA3222159A1/en active Pending
- 2022-06-03 US US17/832,038 patent/US20230032141A1/en active Pending
- 2022-06-03 KR KR1020247000358A patent/KR20240034746A/ko unknown
- 2022-06-03 JP JP2023574534A patent/JP2024520691A/ja active Pending
- 2022-06-03 AU AU2022283922A patent/AU2022283922A1/en active Pending
- 2022-06-03 EP EP22747156.2A patent/EP4347833A2/en active Pending
- 2022-06-06 TW TW111120922A patent/TW202317763A/zh unknown
- 2022-11-04 US US18/052,801 patent/US11821012B2/en active Active
-
2023
- 2023-12-29 CO CONC2023/0018656A patent/CO2023018656A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4347833A2 (en) | 2024-04-10 |
US20230032141A1 (en) | 2023-02-02 |
IL308803A (en) | 2024-01-01 |
CA3222159A1 (en) | 2022-12-08 |
US20230212541A1 (en) | 2023-07-06 |
WO2022256642A3 (en) | 2023-01-12 |
AU2022283922A1 (en) | 2023-12-07 |
KR20240034746A (ko) | 2024-03-14 |
TW202317763A (zh) | 2023-05-01 |
AU2022283922A9 (en) | 2023-12-14 |
US11821012B2 (en) | 2023-11-21 |
WO2022256642A2 (en) | 2022-12-08 |
JP2024520691A (ja) | 2024-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021019722A2 (pt) | Compostos de piperidina 3-substituídos para inibição de cbl-b, e uso de inibidor de cbl-b em combinação com vacina contra câncer e/ou vírus oncolítico | |
BR122021025194A8 (pt) | Molécula de ácido nucleico, método para obter rna, rna, método para obter um peptídeo ou proteína e usos in vitro ou ex vivo do rna | |
BR112022017735A2 (pt) | Métodos e composições de supressão de defesa de hospedeiro para modular um genoma | |
AR098300A1 (es) | Locus óptimos de la soja | |
BR112017024331A2 (pt) | composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto | |
CO2018012099A2 (es) | Composiciones y métodos para programar células terapéuticas utilizando nanoportadores de ácidos nucleicos dirigidos | |
BR112022012921A2 (pt) | Métodos para editar de forma alvejada ácido ribonucleico e para tratar a síndrome de usher tipo ii, ácido ribonucleico de recrutamento da adenosina desaminase, construto ou vetor de entrega, célula, e, uso do ácido ribonucleico de recrutamento da adenosina desaminase ou do construto ou vetor de entrega | |
MX2023006566A (es) | Sistemas crispr tipo v clase 2 diseñados por ingeniería. | |
AR088754A1 (es) | Metodos y composiciones para el control de malezas | |
BR112013026494A2 (pt) | composto, composição farmacêutica, método para tratar condição | |
CO2021002691A2 (es) | Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1) | |
EP3656873A3 (en) | Polynucleotide enrichment and amplification using argonaute systems | |
CL2021001490A1 (es) | Constructos de iarn modificados químicamente y usos de estos | |
AR104024A1 (es) | Métodos y composiciones para la introgresión acelerada de rasgos | |
BR112022024501A2 (pt) | Construtos de rnai para inibir a expressão de hsd17b13 e métodos de uso dos mesmos | |
BR112018008344A2 (pt) | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, método para prevenir, tratar ou melhorar uma doença, e, uso de uma composição | |
BR112021007403A2 (pt) | Composições e métodos para entrega de transgenes | |
BR112017018861A2 (pt) | métodos para tratar câncer mantendo perda hemizigótica de tp53 | |
Osaki et al. | Diphenyleneiodonium chloride, an inhibitor of reduced nicotinamide adenine dinucleotide phosphate oxidase, suppresses light-dependent induction of clock and DNA repair genes in zebrafish | |
MX2022001080A (es) | Metodos y composiciones para reducir la inmunogenicidad mediante inhibidores de celulas b no agotadores. | |
EA201070229A1 (ru) | Нуклеотидные последовательности msca1, влияющие на мужскую фертильность растений, и способ их применения | |
BR112022001230A2 (pt) | Estratégia de design de doador para edição de genoma crispr-cas9 | |
CO2023016031A2 (es) | Composiciones y métodos para el direccionamiento genético in vivo mediado por nucleasas para el tratamiento de trastornos genéticos | |
CO2023018656A2 (es) | Sistemas de edición de genes que comprenden un arn guía dirigido a hidroxiácido oxidasa 1 (hao1) y usos de estos | |
BR112021021149A2 (pt) | Métodos e composições para a geração de alelos dominantes utilizando a edição de genomas |